The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer

Anticancer Research

Volumn 17, Issue 6 D, 1997, Pages 4717-4721

  Strang, P ^a   Nilsson, S ^b   Brandstedt S ^c   Sehlin, J ^c   Borghede, G ^d   Varenhorst, E ^e   Bandman, U ^f   Borck, L ^f   Englund, G ^g   Selin, L ^h  

^a LINKÖPING UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c DANDERYD HOSPITAL   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e Norrköpings Hospital

^f Eskilstuna Hospital   (Sweden)

^g ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^h Astra Lakemedel Lakemedel AB   (Sweden)

Author keywords

Bone pain; Cancer; Clodronate; Prostate

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID;

ADULT; AGED; ANALGESIA; ARTICLE; BONE METASTASIS; BONE PAIN; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; ANALGESICS, NON-NARCOTIC; BONE NEOPLASMS; CLODRONIC ACID; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PLACEBOS; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS;

EID: 6844236996     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Koslowski J, Ellis W, Grayhack J: Advanced prostatic carcinoma - early versus late endocrine therapy. Urol Clin North Am 18: 15-24, 1991.
2. Tofe A, Francis M, Harvey W: Correlation of neoplasms with incidence and localization of skeletal metastases: An analysis of 1355 diphosphonate bone scans. J Nucl Med 16: 986-989, 1975.
3. Bruera E, Roca E, Cedaro L et al: Action of oral methyl prednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 69: 751-754, 1985.
4. Arcangeli G, Micheli A, Arcangeli G et al: The responsiveness of bone metastases to radiotherapy: The effect of site, histology and radiation dose on pain relief. Radiother Oncol 14: 95-101, 1989.
5. Blitzer P: Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis. Cancer 55: 1468-1472,1985.
6. Crawford E, Kozlowski J, Debruyne F et al: The use of strontium 89 for palliation of pain from bone metastases associated with hormone-refractory prostate cancer. A clinical review. Urol 44: 481-485,1994.
7. Jonsson B, Sjostrom L, Olerud C, Andreasson I, Bring J, Rauschning W: Outcome after limited posterior surgery for thoracic and lumbar spine metastases. Eur Spine J 5: 36-44, 1996.
8. Kanis J, McCloskey E, Paterson A: Use of diphosphonates in hypercalcemia due to malignancy. Lancet i, 170-171,1990.
9. Paterson A, Powles T, Kanis J et al: Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11: 59-65, 1993.
10. Lahtinen R, Laakso, Palva I, et al (The Finnish Leukemia group): Randomised placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 340 (8827): 1049-1052, 1992.
11. Adami S, Mian M: Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. Recent Results in Cancer Res 116: 67-72, 1989.
12. Vorreuther R: Biphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma. A pilot study on clodronate. Br J Urol 72: 792-795, 1993.
13. Cresswell S, English P, Hall R, Roberts J, Marsh M: Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer. Br J Urol 76: 360-365, 1995.
14. Robertson A, Reed N, Ralston S: Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol 9: 2427-2430, 1995.
15. Ernst D, MacDonald R, Paterson A et al: A double-blind, cross-over trial of intravenous clodronate in metastatic bone pain. J Pain Sympt. Man 7: 4-11, 1992.
16. Kylmala T, Tammela, T, Lindholm T, Seppanen J: The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer. Ann Chir Gynecol 83: 316-319, 1994.
17. Martin H, Basbaum A, Goetz E, Levine J: Leukotriene B4 decreases the mechanical and thermal thresholds of C fiber nociceptors in the hairy skin of the rat. J Neurophysiol 60: 438-445,1988.
18. Felix R, Bettex J-D, Fleisch H: Effect of diphosphonates on the synthesis of prostaglandins in cultured calvaria cells. Calcif Tissue Int 33: 549-552, 1981.
19. Ohya K, Yamada S, Felix R et al: Effect of bisphosphonates on prostaglandin synthesis by rat bone cells and mouse calvaria in culture. Clin Sci 69: 409-411, 1985.
20. Morgan D, Monod A, Russell R, Fleisch H: Influence of dichloromethylene diphosphonate (C12MDP) and calcitonin on bone resorption, lactate production and phosphatase and pyrophosphatase content of mouse calvaria treated with parathyroid hormone in vitro. Calcif Tissue Res 13: 287-294, 1973.
21. Fast D, Felix R, Dowse C, Neumann W, Fleisch H: The effects of diphosphonates on the growth and glycolysis of connective-tissue cells in culture. Biochem J 772: 97-107, 1978.
22. Felix R, Russell R, Fleisch H: The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes. Biochim Biophys Acta 429: 429438,1976.
23. Emonds-Alt X, Breliere J-C, Ronucci R: Effects of 1-hydroxyethylidene-1,1 bisphosphonate and (chloro-4 phenyl) thiomethylene bisphosphonic acid (SR 41319) on the mononuclear cell factor-mediated release of neutral proteinases by articular chondrocytes and synovial cells. Biochem. Pharmacol 34: 4043-4049, 1985.
24. Merlini G, Parrinello A, Piccini L et al: Long-term effects of parenteral dichloromethylene bisphosphonate (C12MDP) on bone disease of myeloma patients treated with chemotherapy. Hematol Oncol 1990, 8;23-33.
25. Elomaa I, Kylmala T, Tammela T, et al: Effect of oral clodronate on bone pain. A controlled study in patients with mestastatic prostatic cancer. Int J Urol Nephrol 24(2): 159-166,1992.
26. Portenoy, R: Cancer pain, epidemiology and syndromes. Cancer 63: 2298-2307, 1989.
27. Strang P, Qvarner H: Cancer-related pain and its influence on quality of life. Anticancer Res 10: 109-112,1990.
28. Strang P: Emotional and social aspects of cancer pain. Acta Oncol 31: 323-326, 1992.
29. Kelsen D, Portenoy R, Thaler H et al: Pain and depression in patients with newly diagnosed pancreas cancer. J Clin Oncol 13: 748-755, 1995.
30. Heim H, Oei T: Comparison of prostate cancer patients with and without pain. Pain 53: 159-162, 1993
31. Spiegel D, Sands S, Koopman C: Pain and depression in patients with cancer. Cancer 74: 2570-2578, 1994.
32. Strang P: Existential consequences of unrelieved cancer pain. Palliat Med 11: 299-305, 1997.
33. WHO: Cancer pain relief. WHO, Geneve 1986. 74 pp.
34. Elomaa I, Blomqvist C, Grohn P et al: Long-term controlled trial with diphosphonate in patients with osteolytic bone disease. Lancet 1: 146-149,1983.
35. Lipton A, Glover H, Harvey S et al: Pamidronate in the treatment of bone metastases: Results of 2 dose-ranging trials in patients with breast or prostate cancer. Ann Oncol 5 (Suppl 7): S31-S36,1994.
36. Conte P, Giannessi J, Latreille L et al: Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised multicenter phase III trial. Ann Oncol 5 (Suppl 7): S41-S44, 1994.
37. Berenson J, Lichtenstein A, Porter L et al: Efficacy of pamidronate in reducing skeletal event in patients with advanced multiple myeloma. New Engl J Med 334: 488-493, 1996.
38. Adami S, Salvagno G, Guarrera G et al: Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol 134: 1152-1154, 1985.
39. Clarke N, McClure, J, George N: Osteoblast function and osteomalacia in metastatic prostate cancer. Eur Urol 24: 286-290,1993.